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Many xenobiotics including the pharmacoenhancer
cobicistat increase serum creatinine by inhibiting its renal
active tubular secretion without affecting the glomerular
filtration rate. This study aimed to define the transporters
involved in creatinine secretion, applying that knowledge to
establish the mechanism for xenobiotic-induced effects. The
basolateral uptake transporters organic anion transporter
OAT2 and organic cation transporters OCT2 and OCT3 were
found to transport creatinine. At physiologic creatinine
concentrations, the specific activity of OAT2 transport was
over twofold higher than OCT2 or OCT3, establishing OAT2
as a likely relevant creatinine transporter and further
challenging the traditional view that creatinine is solely
transported by a cationic pathway. The apical multidrug and
toxin extrusion transporters MATE1 and MATE2-K
demonstrated low-affinity and high-capacity transport. All
drugs known to affect creatinine inhibited OCT2 and MATE1.
Similar to cimetidine and ritonavir, cobicistat had the
greatest effect on MATE1 with a 50% inhibition constant of
0.99lM for creatinine transport. Trimethoprim potently
inhibited MATE2-K, whereas dolutegravir preferentially
inhibited OCT2. Cimetidine was unique, inhibiting all
transporters that interact with creatinine. Thus, the clinical
observation of elevated serum creatinine in patients taking
cobicistat is likely a result of OCT2 transport, facilitating
intracellular accumulation, and MATE1 inhibition.
Kidney International (2014) 86, 350–357; doi:10.1038/ki.2014.66;
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A number of drugs from different therapeutic classes have
been observed to reduce creatinine clearance without causing
an effect on the rate of glomerular filtration (Supplementary
Table S1 online).1–13 The most prominent effects, increases
in serum creatinine levels between 0.2 and 0.4mg/dl and
decreases in creatinine clearance of 15–34ml/min per 1.73m2,
have been noted with the antacid cimetidine,1 a number of
antibiotics including trimethoprim,4 and the antiparasitic
pyrimethamine.5 Most recently, more modest effects (serum
creatinine increases of B0.1mg/dl) have been observed for
the antiretroviral drugs rilpivirine and dolutegravir,6,7 and
the pharmacoenhancers cobicistat and ritonavir.8,13 Similar
to other drugs, cobicistat was established to not have an
adverse effect on renal function in a clinical study showing
no change in the glomerular filtration rate, as measured by
iohexol clearance.8
The effects on creatinine observed with these drugs have
been attributed to the inhibition of the renal active tubular
secretion component of creatinine clearance.14 In subjects
with normal renal function, active tubular secretion accounts
for 10–40% of creatinine clearance.15 In contrast to the
passive filtration occurring at the glomerulus, active tubular
secretion in the proximal tubule is mediated by specific
transport proteins that can be subject to inhibition by
xenobiotics.16,17 Although creatinine has been shown to be a
substrate for a number of transporters in the solute carrier
(SLC) superfamily expressed in renal proximal tubules, the
predominant pathway mediating creatinine secretion has not
been fully elucidated. Creatinine has been shown to be a
substrate for a cation transport pathway comprising the
basolaterally expressed organic cation transporter 2 (OCT2;
SLC22A2)18–20 and the apically expressed multidrug and
toxin extrusion (MATE) transporters 1 (SLC47A1) and 2-K
(SLC47A2).21 However, the absolute contribution of OCT2
to the basolateral uptake of creatinine has been called into
question by recent studies in mice. Knockout of OCT2 did
not affect serum creatinine in one report.22 Another study
has suggested a role for basolaterally expressed anionic
transporters.23
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In the current study, we sought to understand the mole-
cular mechanism for increases in serum creatinine observed
clinically with cobicistat. Cobicistat is a mechanism-based
inhibitor of cytochrome P450 3A enzymes approved as
part of a fixed-dose, once-daily, single-tablet regimen for
the treatment of HIV (brand name STRIBILD) containing
the nucleotide reverse transcriptase inhibitors tenofovir
disoproxil fumarate and emtricitabine and the integrase
inhibitor elvitegravir. Other antiviral combinations contain-
ing cobicistat are also being explored.24,25 Studies were
conducted in two parts: in part one, the mechanism of the
active tubular secretion of creatinine was explored in vitro
using refined transient transfection techniques, allowing for
a better understanding of the relative contributions of
individual transporters to creatinine transport. In part two,
the interaction of cobicistat and other drugs with identified
creatinine transporters was characterized. In addition to
gaining novel insights regarding the mechanism of creatinine
secretion, we elucidate the molecular mechanism for the
effect of cobicistat on serum creatinine, providing a more
comprehensive framework for understanding xenobiotic-
induced changes in the renal handling of creatinine.
RESULTS
Identification of creatinine transporters
Madin–Darby canine kidney cells (MDCKII) were transfected
with the human sequences encoding basolaterally expressed
OCT1 (SLC22A1), OCT2, OCT3 (SLC22A3), organic anion
transporters OAT1 (SLC22A6), OAT2 (SLC22A7), and OAT3
(SLC22A8), and apically expressed MATE1, MATE2-K, OAT4
(SLC22A11), and organic cation transporter novel (OCTN),
type 1 (SLC22A4), and type 2 (SLC22A5). Transporter
expression was confirmed by quantitative mRNA analysis and
at the functional level with model substrates (Supplementary
Figures S1 and S2 online).
Transporter-dependent and inhibitor-sensitive transport
of creatinine was observed for the basolateral transporters
OCT2, OCT3, and OAT2 (Figure 1a), and apical transporters
MATE1 and MATE2-K (Figure 1b). Model inhibitors caused
creatinine uptake into cells overexpressing these transporters
to be reduced to levels observed in nontransfected cells. To
facilitate comparison with background creatinine accumu-
lation in control cells, data in Figure 1 are normalized to
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Figure 1 | Creatinine transport by renal transporters in polarized
Madin–Darby canine kidney II (MDCKII) cells. Uptake of creatinine
(100 mmol/l) by (a) basolateral and (b) apical renal transporters.
Results are shown for transporter-transfected cells relative to
matched cells transfected with green fluorescence protein (GFP) in
the presence and absence of inhibitors incubated at ten times the
respective concentrations required to inhibit transport by 50% for
each transporter (100mmol/l probenecid (OAT1 and OAT3), 100 or
200 mmol/l indomethacin (OAT2 and OAT4, respectively), 1mmol/l
quinidine (OCT1, OCT2, OCT3, and OCTN1), 100mmol/l cimetidine
(MATE1 and MATE2-K), and 500 mmol/l verapamil (OCTN2)). Each
value represents the mean±s.d. of three measurements. The
statistical significance of the change in the ratio of accumulation in
transporter-transfected cells relative to GFP control in the presence
and absence of inhibitor was assessed using a Student’s unpaired
and two-tailed t-test assuming equal variance (***Po0.001; and
****Po0.0001). The concentration dependence of creatinine uptake
by the basolateral transporters organic anion transporter OAT2 and
organic cation transporters OCT2 and OCT3 is presented in panel c.
Data fit by nonlinear curve fitting to a hyperbolic equation. MATE,
multidrug and toxin extrusion; OAT, organic anion transporter; OCT,
organic cation transporter.
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surface area. Analysis of accumulation based on mRNA
expression in units of pmol/min per mRNA copy number did
not markedly change the rank order of transport, with the
exception of OCT3 having an apparently twofold higher
rate than OCT2 and MATE2-K having an apparently sixfold
higher rate than MATE1 owing to correspondingly lower
relative mRNA expression of OCT3 and MATE2-K in the
transfection system (Supplementary Figure S1 online).
In contrast to our study, two prior studies have reported
creatinine transport by human OAT3 in different transfection
systems.19,20 For example, Ciarimboli et al.19 reported a 60%
increase in creatinine accumulation over mock transfection
in transiently transfected human embryonic kidney 293
(HEK293) cells. To assure that the background cell type did
not affect our ability to detect OAT3-dependent creatinine
transport, we assessed accumulation in transiently transfected
HEK293 cells. In agreement with results from our MDCKII
transfection system, no OAT3-dependent transport of creati-
nine was observed in HEK293 cells (data not shown).
Kinetics of creatinine transport
Kinetic constants for creatinine transport by the five identi-
fied transporters were determined (Table 1 and Figure 1c).
Among the three basolateral transporters, OAT2 showed the
highest affinity (Km¼ 986 mmol/l) and most rapid maximal
velocity (Vmax¼ 117104 pmol/min per mRNA copy num-
ber) for creatinine. The transport rate at a physiological
creatinine concentration (100 mmol/l) for OAT2 was 4.7- and
2.3-fold faster than that measured for OCT2 and OCT3,
respectively. Kinetic constants for the apical transporters
MATE1 and MATE2-K could not be accurately determined
owing to their weak binding constants for creatinine
(Km42000 mmol/l) under the experimental conditions. The
inefficient transport observed for these transporters may be
related to the artificial experimental conditions where uptake
is studied instead of physiologically relevant efflux by
manipulating extracellular pH.
Inhibition of creatinine transporters by cobicistat and other
drugs
Inhibition of the creatinine transporters identified above by
cobicistat and other drugs reported to affect serum creatinine
was studied using transfected cell lines and model substrates.
Dose–response curves for each transporter are presented in
Figure 2, and inhibition constants are summarized in Table 2.
All compounds known to affect serum creatinine were
found to inhibit OCT2 and MATE1. Similar to cimetidine
and ritonavir, cobicistat most potently inhibited MATE1
(half-maximal inhibitory concentration (IC50)¼ 1.87 mmol/l)
with a weaker effect on the other transporters. Of the baso-
lateral uptake transporters, cobicistat showed weak inhibition
of OCT2 (IC50¼ 24 mmol/l), with little or no inhibition of
OCT3 and OAT2 (IC504100 mmol/l). Dolutegravir was
found to be one of the most potent OCT2 inhibitors
reported to date based on its effect on tetraethylammonium
transport (IC50¼ 0.066 mmol/l). The potent inhibition by
dolutegravir was confirmed in a separate assay by the obser-
vation of similar inhibition of OCT2-dependent metformin
transport (IC50¼ 0.11 mmol/l). These results are consistent
with the relatively potent OCT2 inhibition by dolutegravir
reported elsewhere.26 Trimethoprim was found to be a rela-
tively potent inhibitor of MATE2-K. Cimetidine was unique
in its inhibition of all creatinine transporters.
To establish the physiological relevance of results obtained
with model substrates, IC50 values for cimetidine and
cobicistat were determined for OAT2-, OCT2-, and MATE1-
mediated creatinine transport (Supplementary Figure S3
online). The observation of substrate-dependent inhibition
would not be anticipated on the basis of the lack of a marked
difference in the cimetidine inhibition constants (Ki) for a
panel of cationic transporters measured with five different
substrates reported in a recent comprehensive study.27
Studies with creatinine confirmed results obtained with
model substrates showing MATE1 to be the most sensitive
transporter to inhibition by cobicistat and cimetidine (IC50
values 0.99 and 0.20 mmol/l, respectively). The increased
potencies observed for the tested transporters relative to
assays completed with model substrates incubated at their
respective Km values are consistent with the observation of
a competitive mode of inhibition and a creatinine concen-
tration substantially below Km.
Uptake of cobicistat by renal transporters
To explore the possibility that cobicistat accumulation in
proximal tubule cells has a role in serum creatinine elevations
observed clinically, we assessed the uptake of cobicistat into
Table 1 | Kinetic constants for creatinine transport by renal transporters tested in transiently transfected cell models
Km (lmol/l)
Vmax (104 pmol/min
per mRNA copy number) Efficiency (Vmax/Km)
Physiologic rate (104pmol/min
per mRNA copy number)a
OAT2 986±177 117±6 0.119 9.25±1.44
OCT2 1860±370 42.1±2.4 0.023 1.97±0.30
OCT3 1320±380 68.2±7.1 0.052 3.99±0.52
MATE1 42000 42 ND 0.23±0.04
MATE2-K 42000 420 ND 1.32±0.41
Abbreviations: MATE, multidrug and toxin extrusion; MATE1 and MATE2-K, multidrug and toxin extrusion transporters 1 and 2-K; ND, not determined; OAT2, organic anion
transporter 2; OCT2 and OCT3, organic cation transporters 2 and 3.
Kinetic constant derived from nonlinear curve fitting plus/minus s.e. based on the concentration dependence of creatinine transport from nX3 independent experiments.
aRate determined at 100 mmol/l creatinine.
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fresh human primary proximal tubule cells and cell lines
overexpressing individual transporters. Assessing cobicistat
accumulation in cells was technically challenging because of
the high levels of nonspecific membrane association observed
for this lipophilic drug. Addition of protein to the incubation
and isolation of cells by spinning through oil reduced the
background to allow observation of transporter-dependent
uptake (see Materials and Methods). Although transporter
activity is variable and progressively declining after isolation,
evidence for transporter-dependent uptake of cobicistat was
observed in freshly isolated primary proximal tubule cells
based on small but reproducible decreases in accumulation in
the presence of the transport inhibitors cimetidine or
probenecid (Figure 3a). To better characterize the molecular
mechanism for cobicistat accumulation in proximal tubule
cells, uptake studies were completed in cells overexpressing
individual basolateral uptake transporters. OCT2 and OAT3
were selected on the basis of the apparent sensitivity of
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Figure 2 | Inhibition of creatinine transporters. Inhibition of multidrug and toxin extrusion transporters (a) MATE1 and (b) MATE2-K, organic
cation transporters (c) OCT2 and (d) OCT3, and organic anion transporter (e) OAT2 mediated transport of model substrates by cimetidine,
trimethoprim, dolutegravir, cobicistat, and ritonavir. The concentration-dependent inhibition data are fit by nonlinear curve fitting to a
sigmoidal equation. Curves could not be generated for inhibition of OCT3-dependent transport by cobicistat and dolutegravir, and OAT2-
dependent transport by dolutegravir, ritonavir, and trimethoprim, owing to a lack of concentration-dependent inhibition. Data represent
the average of two to three independent determinations of the concentration-dependent inhibition by each inhibitor. MATE, multidrug
and toxin extrusion.
Table 2 | Inhibition of the transport of model substrates by
transporters identified to transport creatinine by drugs that
reduce the active tubular secretion of creatinine
IC50 (lmol/l)
OAT2 OCT2 OCT3 MATE1 MATE2-K
Cimetidine 72.8±17.0 135±16 87.7±55.1 1.46±0.11 46.6±7.23
Trimethoprim 4300 68.0±5.2 12.3±5.2 3.31±0.67 1.87±0.57
Cobicistat 4100 24.0±4.6 4100 1.87±0.22 33.5±4.2
Ritonavir 420 B20 420 1.34±0.23 420
Dolutegravir 4100 0.066±0.003 4100 4.67±1.11 4100
Abbreviations: IC50, half-maximal inhibitory concentration; MATE1 and MATE2-K,
multidrug and toxin extrusion transporters 1 and 2-K; OAT2, organic anion
transporter 2; OCT2 and OCT3, organic cation transporters 2 and 3.
Inhibition constants were measured for OAT2 transport of 30 , 50-cyclic GMP, OCT3
transport of 1-methyl-4-phenylpyridinium, and OCT2, MATE1, and MATE-2K
transport of tetraethylammonium.
Inhibition by compounds was studied by threefold serial dilution up to 20mmol/l
(ritonavir), 100mmol/l (cobicistat and dolutegravir), and 300 mmol/l (cimetidine and
trimethoprim). The highest concentrations tested were based on aqueous solubility
limits.
IC50 values represent the average plus/minus s.e.m. from curve fitting of at least
two measurements per inhibitor concentration.
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cobicistat accumulation to cimetidine and probenecid in
proximal tubule cells and evidence for some molecular
interaction provided by the weak inhibition of these
transporters by cobicistat reported here and elsewhere.28 A
2.9-fold increase in cobicistat accumulation was observed in
cells transfected with OCT2 (Figure 3c). Uptake in OCT2-
expressing cells was reduced to that of nontransfected cells in
the presence of OCT2 inhibitors. Although quinidine caused
a significant increase in cobicistat accumulation in non-
transfected cells, likely related to the inhibition of p-glyco-
protein-mediated cobicistat efflux, it completely inhibited the
uptake transport in OCT2-expressing cells, reducing accu-
mulation to levels observed in nontransfected cells in the
absence of inhibitor. In contrast, no inhibitor-sensitive
accumulation of cobicistat was observed in cells transfected
with OAT3 (Figure 3e). Transporter expression was estab-
lished in the different systems with the use of model
substrates (Figure 3b, d, and f).
DISCUSSION
In patients with normal renal function, creatinine is
primarily eliminated by glomerular filtration, and it can be
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Figure 3 | Uptake transport of cobicistat by renal transporters. (a) The uptake of cobicistat (1 mmol/l) was assessed in fresh isolated primary
proximal tubule cells in the presence of a model cationic transport inhibitor cimetidine (1500 mmol/l) and anionic transport inhibitor
probenecid (90 mmol/l). (b) The cimetidine-sensitive uptake of the model cationic substrate tetraethylammonium or probenecid-sensitive
anionic substrate esterone-3-sulfate was determined by establishing transporter expression in the primary proximal tubule cells. The effect of
OCT2 or OAT3 expression on the intracellular accumulation of cobicistat (1 mmol/l) was assessed in transfected cell lines. (c) The effect of
inhibitors on levels of cobicistat in parental (nontransfected) or Madin–Darby canine kidney II (MDCKII) cells transfected with the organic cation
transporter OCT2 were assessed in the presence or absence of the OCT2 inhibitors cimetidine (1500 mmol/l) or quinidine (200 mmol/l). (d) The
inhibitor-sensitive accumulation of the known OCT2 substrate tetraethylammonium was determined, establishing appropriate OCT2
expression. (e) The effect of inhibitors on levels of cobicistat in human embryonic kidney 293 (HEK293) cells either mock-transfected or
transfected with the organic anion transporter OAT3 were assessed in the presence or absence of the OAT3 inhibitors diclofenac or probenecid
both incubated at 90 mmol/l. (f) The inhibitor-sensitive accumulation of the known OAT3 substrate esterone-3-sulfate was determined,
establishing appropriate OAT3 expression. Data represent the average±s.d. of three independent assays performed in triplicate. The statistical
significance of differences between conditions was assessed using the Student’s unpaired and two-tailed t-test assuming equal variance
(*Po0.05; **Po0.005; ***Po0.001; and ****Po0.0001).
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used as a convenient means for estimating the glomerular
filtration rate. Therefore, measurement of serum creatinine
levels is the most common method used clinically for the
routine monitoring of renal function. It is important to
understand which xenobiotics have the potential to elevate
serum creatinine without causing an effect on the rate of
glomerular filtration to interpret correctly changes upon
initiation of therapy. In elucidating the molecular mechanism
for the elevation of serum creatinine with cobicistat, we have
obtained novel insights that should help in the prediction of
the potential of other drugs to affect creatinine clearance.
The active tubular secretion of creatinine has traditionally
been believed to be mediated by an entirely cationic pathway,
with the basolateral transporter OCT2 serving as the primary
means of uptake into proximal tubules.18–20 Eisner et al.22
called into question the relative role of Oct2 in mice
by showing inhibition of creatinine secretion by the anion
para-aminohippurate and the lack of an effect of Oct1/Oct2
knockout. This result has generated controversy, with
another group reporting a decrease in creatinine secretion
in the same knockout system and suggesting that the
contrasting results may be due to the use of ketamine
anesthesia in the earlier report, as ketamine itself has the
potential to interfere with creatinine secretion.19 Supporting
a role of anionic transporters in creatinine secretion across
species, inhibitors of anionic transporters have been noted to
affect renal creatinine secretion in a number of species
including humans.22,23,29–34 Adding further support for the
role of anion transporters in creatinine secretion, Vallon
et al.23 found that mouse Oat1 and Oat3 can transport creati-
nine in vitro, that this transport was inhibited by cimetidine,
and that Oat3-knockout mice had blunted creatinine
secretion in vivo. While providing a more comprehensive
understanding of the role of Oat3 in creatinine secretion in
mice, species differences in transporter expression and
substrate specificity may affect the relevance of this finding
to humans. Indeed, it is more problematic to propose
OAT3 as the predominant basolateral transporter in humans
given the minimal transport activity detected by human
OAT3 by others,19,20 and the complete lack of OAT3-
mediated transport observed in well-controlled assays in
two separate cell backgrounds in the current study. OAT2 is
expressed on the basolateral membrane of the proximal
tubule in humans, and it has been reported to have threefold
higher mRNA expression levels than OCT2.35 Therefore, our
observation that OAT2 facilitates the most efficient transport
of creatinine in vitro of any of the human creatinine
transporters identified, coupled with high expression levels
in proximal tubules, suggests that it may make a substantial
contribution to creatinine secretion in man and further
establishes the more general involvement of anionic
transporters in creatinine secretion.
A recent paper also reported OAT2-dependent transport
of creatinine.19 However, in contrast to our observation of
relatively efficient creatinine transport, OAT2 was found to
cause markedly less accumulation than that facilitated by
OCT2 or OCT3. However, transporter expression and the
kinetics of creatinine transport were not determined in this
study. Stably transfected cell lines generated in different labo-
ratories are known to have variable transporter expression.
Therefore, we used highly optimized transient transfection
techniques and characterized cells for mRNA and functional
transporter expression. This rigorous characterization of the
test system makes us confident in the observations described
in the current report.
Although the mechanism of basolateral uptake of
creatinine into the proximal tubule is being debated, MATE
transporters have emerged as the likely mechanism for apical
efflux into the urine across species. Serum creatinine levels
are increased in mice lacking MATE1.36 In addition to
findings in mice, the availability of a potent and relatively
selective inhibitor of MATE transporters, something unfortu-
nately unavailable for basolateral transporters, provides the
most compelling evidence for their role in creatinine
secretion. Pyrimethamine is a potent and selective inhibitor
of MATE1 and MATE2-K (Ki values of 93 and 59 nmol/l,
respectively),37 and it causes large increases in serum
creatinine clinically.5 In the current investigation, we found
MATE1 and MATE2-K to be the only apical transporters able
to transport creatinine. It was notable that all drugs known to
increase serum creatinine were potent inhibitors of MATE1
(IC50 o5 mmol/l), with only trimethoprim and dolutegravir
more potently inhibiting another creatinine transporter.
Although cimetidine most potently inhibited MATE1,
the observation of inhibition of all creatinine transporters
provides a possible explanation for why high-dose cimetidine
can completely block creatinine secretion, reducing its
clearance to a level that approximates the glomerular filtra-
tion rate.1
Clinically, cobicistat achieves a maximum plasma con-
centration of 1.4 mmol/l, over 90% of which is bound to
plasma proteins. Therefore, cobicistat would have to achieve
concentrations in proximal tubule cells that are substantially
above free concentrations in plasma, approaching total,
to inhibit MATE1-dependent creatinine transport in a
manner consistent with clinically observed elevations in
serum creatinine. Our results show that cobicistat is taken
up by proximal tubule cells, mediated at least in part by
OCT2. Furthermore, the limited renal elimination of
cobicistat (approximately 8% in humans) suggests that
accumulation within cells is possible. The proposed mechan-
ism for creatinine secretion and inhibition by cobicistat is
presented in Figure 4. Cellular accumulation resulting in
the inhibition of efflux transport is likely a more general
mechanism for drugs that inhibit creatinine secretion.
The same mechanism has been proposed previously for the
inhibition of the active tubular secretion of metformin by
cimetidine, whereby intracellular levels of cimetidine are
increased by OCT2-dependent uptake.27
In summary, we have further elucidated the transporters
involved in creatinine secretion and delineated a common
mechanism of MATE1 inhibition for xenobiotic-induced
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changes in creatinine elimination. The novel insight that an
organic anion transporter, OAT2, facilitates creatinine
transport with relatively high efficiency furthers the evidence
for the involvement of anionic transporters in creatinine
secretion. For cobicistat, uptake into the proximal tubule,
mediated at least in part by OCT2, facilitates intracellular
accumulation and inhibition of apically expressed MATE1.
These findings focus attention on the importance of
determining uptake transport and resulting cellular accumu-
lation when predicting the potential for clinically relevant
transporter inhibition, and further elucidate the mechanism
whereby some drugs artificially affect creatinine-based
measurements that are routinely used clinically to assess
renal function.
MATERIALS AND METHODS
See Supplementary Material online for more detailed description of
methods including reagents, cell lines, and culturing conditions.
Creatinine transport assays
Transiently transfected MDCKII cells were preincubated with Hank’s
balanced salt solution in the presence (MATE1 and MATE2-K only)
or absence (all other transporters) of 30mmol/l NH4Cl for 20min.
Transport assays were initiated by adding the substrate in the
presence or absence of inhibitor in the appropriate chamber of
the insert plate based on apical or basolateral expression of the
respective transporter. The kinetics of uptake by identified creatinine
transporters was determined by using a concentration range of
31 mmol/l to 20mmol/l. After the incubation, the cells were washed
with ice-cold, phosphate-buffered saline four times, and then
extracted using 1:1 acetonitrile:water mixture. The amount of
intracellular substrate was subsequently quantified by radiometric
counting.
Transporter inhibition assays
Model substrate inhibition studies were conducted in stably
transfected Chinese hamster ovary cells (OCT2 and MATE1),
HEK293 cells (MATE2-K), or transiently transfected MDCKII cells
(OAT2 and OCT3). Inhibition of the transport of the radiolabeled
model substrates 30,50-cyclic GMP (2mmol/l; OAT2), 1-methyl-4-
phenylpyridinium (10 mmol/l; OCT3), and tetraethylammonium
(3.6 mmol/l; OCT2 and MATE1; 5 mmol/l; MATE2-K) was deter-
mined. Control inhibitors were tested in each assay: indomethacin
(OAT2), lansoprozole (OCT3), verapamil (OCT2), quinidine
(MATE1), and cimetidine (MATE2-K). Positive control inhibitors
were incubated at concentrations exceeding their reported IC50 for
the respective transporter by at least 10-fold.
Uptake into human proximal tubule cells and cell lines
transfected with OCT2 or OAT3
Briefly, the uptake of cobicistat into recently isolated human
proximal tubule cells or cell lines transfected with OCT2 or OAT3
was studied in medium containing 5% bovine serum albumin and
in the presence or absence of transport inhibitors. Before analysis,
cells were isolated by centrifugation through an oil layer.
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